Sweden
· Delayed Price · Currency is SEK Alligator Bioscience AB Statistics
Total Valuation
Alligator Bioscience AB has a market cap or net worth of SEK 1.00 billion. The enterprise value is 934.90 million.
| Market Cap | 1.00B |
| Enterprise Value | 934.90M |
Important Dates
The next estimated earnings date is Thursday, October 24, 2024.
| Earnings Date | Oct 24, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Alligator Bioscience AB has 758.04 million shares outstanding.
| Shares Outstanding | 758.04M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.83% |
| Owned by Institutions (%) | 8.11% |
| Float | 477.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 19.06 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.99 |
| EV / Sales | 20.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.21 |
Financial Position
The company has a current ratio of 0.67
| Current Ratio | 0.67 |
| Quick Ratio | 0.64 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.05 |
| Interest Coverage | -39.03 |
Financial Efficiency
Return on equity (ROE) is -417.18% and return on invested capital (ROIC) is -198.34%.
| Return on Equity (ROE) | -417.18% |
| Return on Assets (ROA) | -83.49% |
| Return on Capital (ROIC) | -198.34% |
| Revenue Per Employee | 901,039 |
| Profits Per Employee | -4.59M |
| Employee Count | 51 |
| Asset Turnover | 0.27 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +221.95% in the last 52 weeks. The beta is 1.41, so Alligator Bioscience AB's price volatility has been higher than the market average.
| Beta (5Y) | 1.41 |
| 52-Week Price Change | +221.95% |
| 50-Day Moving Average | 1.27 |
| 200-Day Moving Average | 1.02 |
| Relative Strength Index (RSI) | 54.74 |
| Average Volume (20 Days) | 1,033,727 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Alligator Bioscience AB had revenue of SEK 45.95 million and -234.30 million in losses. Loss per share was -0.35.
| Revenue | 45.95M |
| Gross Profit | -142.29M |
| Operating Income | -230.09M |
| Pretax Income | -234.30M |
| Net Income | -234.30M |
| EBITDA | -229.27M |
| EBIT | -230.09M |
| Loss Per Share | -0.35 |
Balance Sheet
The company has 77.51 million in cash and 11.79 million in debt, giving a net cash position of 65.71 million or 0.09 per share.
| Cash & Cash Equivalents | 77.51M |
| Total Debt | 11.79M |
| Net Cash | 65.71M |
| Net Cash Per Share | 0.09 |
| Equity (Book Value) | -9.51M |
| Book Value Per Share | -0.01 |
| Working Capital | -41.76M |
Cash Flow
In the last 12 months, operating cash flow was -222.05 million and capital expenditures -39,000, giving a free cash flow of -222.09 million.
| Operating Cash Flow | -222.05M |
| Capital Expenditures | -39,000 |
| Free Cash Flow | -222.09M |
| FCF Per Share | -0.29 |
Margins
| Gross Margin | n/a |
| Operating Margin | -500.71% |
| Pretax Margin | -509.86% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -483.30% |
Dividends & Yields
Alligator Bioscience AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -26.75% |
| FCF Yield | -22.20% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |